New Evidence Added to the Treatment of Sepsis with Traditional Chinese Medicine


Sepsis is a common complication of infection, severe trauma (burn), shock, and major surgical procedures. In the field of improving the prognosis of sepsis, there are currently no other drugs globally proven to be effective. On May 8th, a reporter from Science and Technology Daily learned that a multidisciplinary team led by Professor Qiu Haibo from the Affiliated Zhongda Hospital of Southeast University found that the traditional Chinese medicine injection Xuebijing can reduce the 28 day all-cause mortality rate of sepsis patients by 7.3%, fully demonstrating the value of traditional Chinese medicine and the combination of traditional Chinese and Western medicine in treating sepsis. The relevant research results were recently published in the international medical journal "Journal of the American Medical Association Internal Medicine". The epidemiological survey in 2020 showed that the proportion of sepsis patients in intensive care units (ICUs) in China was over 20%, and the 28 day mortality rate was over 30%. The treatment of sepsis is also one of the directions that medical research institutions around the world are striving to research. At present, Xuebijing is the only approved traditional Chinese medicine injection for sepsis, which can promote the elimination of inflammatory factors and is mainly used to treat severe patients with organ dysfunction such as sepsis. This clinical study was initiated by Qiu Haibo and collaborated with several 10 research institutions and relevant departments of tertiary hospitals in more than 20 provinces and cities in China. From October 2017 to July 2019, it focused on the core research objective of this field, "case fatality rate", and was conducted using an internationally recognized multicenter, randomized, double-blind controlled study method. It is currently the largest confirmed study on the treatment of sepsis with non antibiotic drugs globally. The research results show that compared to the placebo group, the Xuebijing group reduced the 28 day all-cause mortality rate of sepsis patients by 7.3%, and had a significant effect in reducing ICU mortality and hospital mortality, with reliable clinical safety. (Outlook New Era Network)

Edit:qihang Responsible editor:xinglan

Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era

Recommended Reading Change it